KR910020023A - 헤테로사이클릭-nmda길항제 - Google Patents

헤테로사이클릭-nmda길항제 Download PDF

Info

Publication number
KR910020023A
KR910020023A KR1019910008036A KR910008036A KR910020023A KR 910020023 A KR910020023 A KR 910020023A KR 1019910008036 A KR1019910008036 A KR 1019910008036A KR 910008036 A KR910008036 A KR 910008036A KR 910020023 A KR910020023 A KR 910020023A
Authority
KR
South Korea
Prior art keywords
compound
compound according
hydrogen
alkyl
patient
Prior art date
Application number
KR1019910008036A
Other languages
English (en)
Other versions
KR100196239B1 (ko
Inventor
폴 휘텐 제프리
Original Assignee
개리.디.스트리트
메렐 다우 파마슈티칼즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 개리.디.스트리트, 메렐 다우 파마슈티칼즈 인코포레이티드 filed Critical 개리.디.스트리트
Publication of KR910020023A publication Critical patent/KR910020023A/ko
Application granted granted Critical
Publication of KR100196239B1 publication Critical patent/KR100196239B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

내용 없음

Description

헤테로사이클릭-NMDA길항제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (24)

  1. 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염.
    상기식에서, R1은 수소, C1-4알킬 또는 CF3이고 ; M은 산소, N-O-R4또는(여기서, R4는 수소, C1-4알킬 또는 알킬페닐이다)이며; A는 하기 일반식.
    (여기서, R2는 수소, C1-4알킬, 사이클로알킬, 트리알틸아미노, 알킬페닐, 페닐, 치환된 페닐, 또는 트리플루오로네틸이고 ; R3는 수소, C1-4알킬, 페닐, 알킬페닐, 또는 사이클로헥실메틸이며 ; R5는 수소, 선형 C1-4알킬 또는 알킬페닐이고 ; R6는 수소, C1-4알킬, 페닐, 알킬페닐, 또는 사이클로헥실메틸이다)의 치환체중 어느 하나이다.
  2. 제1항에 있어서, M이 산소인 화합물.
  3. 제1항에 있어서, M이 N-O-R4인 화합물.
  4. 제1항에 있어서, M이인 화합물.
  5. 제1항에 있어서, R3가 수소인 화합물.
  6. 제1항에 있어서, A가 치환체
    인 화합물.
  7. 제1항에 있어서, A가 치환제
    인 화합물.
  8. 제1항에 있어서, A가 치환제
    인 화합물.
  9. 제1항에 있어서, A가 치환제
    인 화합물.
  10. 제8항에 있어서, R5및 R3이 수소인 화합물.
  11. 길항량의 제1항에 따른 화합물을 이를 필요로하는 환자에게 투여함을 특징으로 하여, NMDA 수용체 복합체에 대한 자극성 아미노산의 효과를 길항하는 방법.
  12. 간질 치료량의 제1항에 따른 화합물을 이를 필요로하는 환자에게 투여함을 특징으로 하여, 간질병을 치료하는 방법.
  13. 유효량의 제1항에 따른 화합물을 신경변성질환 환자에게 투여함을 특징으로하여, 신경변성 질환을 치료하는 방법.
  14. 유효량의 제1항에 따른 화합물을 허혈, 저산소증 또는 저혈당증으로 인한 뇌조직 손상 예방을 필요로하는 환자에게 투여함을 특징으로하여, 허혈, 저산소증 또는 저혈당증으로 인한 뇌조직 손상을 예방하는 방법.
  15. 불안치료량의 제1항에 따른 화합물을 이를 필요로하는 환자에게 투여함을 특징으로 하여, 불안증을 치료하는 방법.
  16. 진통량의 제1항에 따른 화합물을 이를 필요로하는 환자에게 투여함을 특징으로 하여, 진통효과를 수득하는 방법.
  17. 약제학적으로 허용되는 담체와 함께 제1항에 따른 화합물을 함유하는 약제학적 조성물.
  18. a)하기 구조(5)의 포스포네이트 에스테르와 하기 구조(6'), (7'), (8') 및 (9')중에서 선택한 적절한 헤테로사이클릭 잔기간에 커플링반응을 수행하고 ; b)생성물을 임의로 탈보호, 보호 및 게속되는 탈보호, 축합, 에스테르화 또는 분리 반응에 적용시킴을 특징으로 하여, 제1항에 다른 화합물을 제조하는 방법.
    상기식에서, R1, R2, R3, R5및 R6는 제1항에서 정의된 바와 같고, Z는 -C(O)-O-alk(여기서, alk는 C1-4선형알킬이다)이며, P는 적합한 보호그룹 또는 H이다.
  19. 약제로서 제1항에 따른 화합물의 용도.
  20. NMDA길항제로서 제1항에 따른 화합물의 용도.
  21. 3-(포스포노아세틸)피페리딘-2-카복실산.
  22. 3(S)-(포스포노아세틸)피페리딘-2(R)-카르복실산.
  23. 약제로서 제21항 또는 제22항에 따른 화합물의 용도.
  24. NMDA 길항제로서 제21항 또는 제22항에 따른 화합물의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개된는 것임.
KR1019910008036A 1990-05-17 1991-05-17 헤테로사이클릭-nmda 길항제 KR100196239B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US52529090A 1990-05-17 1990-05-17
US07/525,290 1990-05-17
US7/525,290 1990-05-17
US07/675,156 US5194430A (en) 1990-05-17 1991-03-28 Heterocyclic-nmda antagonists
US07/675156 1991-03-28
US675156 1991-03-28

Publications (2)

Publication Number Publication Date
KR910020023A true KR910020023A (ko) 1991-12-19
KR100196239B1 KR100196239B1 (ko) 1999-06-15

Family

ID=27061745

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910008036A KR100196239B1 (ko) 1990-05-17 1991-05-17 헤테로사이클릭-nmda 길항제

Country Status (20)

Country Link
US (2) US5194430A (ko)
EP (1) EP0457324B1 (ko)
JP (1) JP2977950B2 (ko)
KR (1) KR100196239B1 (ko)
CN (1) CN1027695C (ko)
AT (1) ATE131172T1 (ko)
AU (1) AU641657B2 (ko)
CA (1) CA2042473C (ko)
DE (1) DE69115116T2 (ko)
DK (1) DK0457324T3 (ko)
ES (1) ES2083478T3 (ko)
FI (1) FI97388C (ko)
GR (1) GR3019047T3 (ko)
HU (1) HU208831B (ko)
IE (1) IE70437B1 (ko)
IL (1) IL98148A (ko)
NO (1) NO300502B1 (ko)
NZ (1) NZ238124A (ko)
PT (1) PT97692B (ko)
TW (1) TW308596B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260286A (en) * 1992-10-16 1993-11-09 Japan Tobacco, Inc. 2-piperidinecarboxylic acid derivatives useful as NMDA receptor antagonists
AU2002250256B2 (en) * 2001-03-08 2008-04-03 Emory University pH-dependent NMDA receptor antagonists
MX2009014216A (es) * 2007-06-29 2010-07-05 Univ Emory Antagonistas del receptor nmda para neuroproteccion.
CN102952130B (zh) * 2011-08-24 2016-03-23 重庆华邦胜凯制药有限公司 手性合成(s,s)-2,8-二氮杂双环壬烷的方法
CN102952065A (zh) * 2011-08-24 2013-03-06 重庆华邦胜凯制药有限公司 一种拆分顺式2,3-吡啶二甲酸酯的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2706194A (en) * 1951-05-14 1955-04-12 Shell Dev Esters of phosphonic acids
NL299936A (ko) * 1963-10-30 1965-08-25
JPS5251028A (en) * 1975-10-22 1977-04-23 Nippon Tokushu Noyaku Seizo Kk Herbicide
US4094974A (en) * 1977-02-24 1978-06-13 Stauffer Chemical Company Isoxazole phosphates and phosphonates
US4139708A (en) * 1977-05-24 1979-02-13 Sk&F Lab Co. Intermediates and processes useful for preparing medicinal agents imidazolemethylphosphonium salts
CA1248531A (en) * 1984-04-17 1989-01-10 Jeffrey C. Watkins 4-substituted piperazine-2-carboxylic acids
US4906621A (en) * 1985-05-24 1990-03-06 Ciba-Geigy Corporation Certain 2-carboxypiperidyl-alkylene phosphonic acids and esters thereof useful for the treatment of disorders responsive to N-methyl-D-aspartate receptor blockade
PH23848A (en) * 1985-05-24 1989-11-23 Ciba Geigy Ag Certain phosphonic acids and derivatives
US4746653A (en) * 1986-02-28 1988-05-24 Ciba-Geigy Corporation Certain hetero phosphonic acid derivatives of 2-piperidine or 2-tetrahydropyridinecarboxylates and esters thereof which are useful for the treatment of disorders responsive to blockade of the NMDA receptor in mammals
US4657899A (en) * 1986-04-09 1987-04-14 Nova Pharmaceutical Corporation Antagonists of specific excitatory amino acid neurotransmitter receptors
EP0275820B1 (de) * 1986-11-21 1991-02-06 Ciba-Geigy Ag Ungesättigte Phosphonsäure und Derivate
SE9003652D0 (sv) * 1990-11-15 1990-11-15 Astra Ab New heterocyclic compounds

Also Published As

Publication number Publication date
DK0457324T3 (da) 1996-01-02
GR3019047T3 (en) 1996-05-31
CA2042473A1 (en) 1991-11-18
JPH0812691A (ja) 1996-01-16
IL98148A (en) 1996-10-16
KR100196239B1 (ko) 1999-06-15
FI97388B (fi) 1996-08-30
PT97692B (pt) 1998-09-30
ATE131172T1 (de) 1995-12-15
AU7649891A (en) 1991-11-21
FI97388C (fi) 1996-12-10
NO911916L (no) 1991-11-18
NZ238124A (en) 1993-09-27
DE69115116D1 (de) 1996-01-18
CN1027695C (zh) 1995-02-22
HU208831B (en) 1994-01-28
CA2042473C (en) 2002-01-01
AU641657B2 (en) 1993-09-30
FI912382A (fi) 1991-11-18
JP2977950B2 (ja) 1999-11-15
EP0457324B1 (en) 1995-12-06
DE69115116T2 (de) 1996-06-13
ES2083478T3 (es) 1996-04-16
EP0457324A1 (en) 1991-11-21
CN1056499A (zh) 1991-11-27
US5470844A (en) 1995-11-28
HU911649D0 (en) 1991-11-28
PT97692A (pt) 1992-02-28
HUT59150A (en) 1992-04-28
FI912382A0 (fi) 1991-05-16
TW308596B (ko) 1997-06-21
IE911676A1 (en) 1991-11-20
IE70437B1 (en) 1996-11-27
US5194430A (en) 1993-03-16
NO911916D0 (no) 1991-05-16
NO300502B1 (no) 1997-06-09

Similar Documents

Publication Publication Date Title
KR900015729A (ko) 흥분성 아미노산 길항제
DE122006000051I2 (de) Ester der 5-Aminolevulinsäure als Mittel zur Photosensibilisierung in der Chemotherapie
OA09368A (fr) "Nouveaux dérivés peptidiques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent".
ATE25974T1 (de) Acyl-substituierte derivate von 1,2,3,4tetrahydroisochinolin-3-carboxysaeuren, ihre salze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung.
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
KR880005092A (ko) 항궤양제로서 유효한 벤즈이미다졸의 신규 유도체
FR2662162B1 (fr) Nouveaux derives de l'amino piperidine, de l'amino pyrrolidine et de l'amino perhydroazepine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
KR890011592A (ko) 기관내 허혈병의 치료용 조성물
PT1514542E (pt) Composição medicamentosa incluindo tacrina ou donepezilo para melhorar as funções cerebrais
FI102964B (fi) Menetelmä terapeuttisesti käyttökelpoisen 4-substituoitu-1-(9,10-dihyd ro-9,10-metanoantrasen-9-yylimetyyli)piperidin-4-olijohdannaisen tuott amiseksi sekä menetelmän välituotteet
KR950005823A (ko) 5-아미노-8-메틸-7-피롤리디닐퀴놀린-3-카르본산유도체
KR900018112A (ko) 흥분성 아미노산 길항제
HU9202642D0 (en) Method for producing piperidine derivatives and pharmaceutical preparatives containing said compounds as active substance
EA199800013A1 (ru) Способы минимизации остеопороза
KR910000607A (ko) 새로운 에스테르
KR910020023A (ko) 헤테로사이클릭-nmda길항제
EP0309424A3 (en) New amidino derivatives
DD283381A5 (de) Verfahren zur herstellung einer verbindung
KR880009934A (ko) 피리딘-2,4-및 2,5-디카복실산 유도체, 이의 제조방법, 이의 용도 및 이들 화합물을 기본으로 하는 약제
KR950701929A (ko) 비정상적인 칼슘 및 인산염 대사를 치료하기 위한 황-함유 포스포네이트 화합물(sulfur-containing phosphonate compounds for treating abnormal calcium and phosphate metabolism)
ATE149165T1 (de) Stickstoff enthaltende bizyklische derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
BG100246A (en) N-substituted azaheterocylic carboxylic acids and their esters
NO178025C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive (benzhydryloksyetylpiperidyl)alifatiske syrederivater
KR930017882A (ko) 아미노 벤조산 유도체
KR930000513A (ko) 헤테로사이클릭 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030212

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee